A sample analysis substrate mountable and detachable to a sample analysis device and includes: a plate-shaped base substrate; and a chamber, the chamber being a space in which to cause a binding reaction, The sample analysis device includes: a motor to rotate the sample analysis substrate; a first magnet unit to attract the magnetic particles; a first actuator to move the first magnet unit to change relative positions of the first magnet unit and the sample analysis substrate; and a control circuit to control the motor, the drive circuit, and the first actuator. The first magnet unit shaped as a whole shape or a partial shape of a circle or a ring. During a B/F separation for separating reacted substance from unreacted substance, the first actuator moves the first magnet unit to a position where the magnetic particles in the chamber are attracted by the first magnet unit.

An example system includes an array of retaining features in a microfluidic cavity, an array of thermally controlled releasing features, and a controller coupled to each releasing feature in the array of releasing feature. Each retaining feature in the array of retaining features is to position capsules at a predetermined location, the capsules having a thermally degradable shell enclosing a biological reagent therein. Each releasing feature in the array of releasing features corresponds to a retaining feature and is to selectively cause degradation of the shell of a capsule. Each releasing feature is to generate thermal energy to facilitate degradation of the shell. The controller is to selectively activate at least one releasing feature in the array of thermally controlled releasing features to release the biological reagent in the capsules positioned at the retaining feature corresponding to the activated releasing feature.

The present disclosure provides a device and method for measuring an amount of an analyte in a sample, comprising a lateral flow matrix which defines a flow path and which comprises, in series: a sample receiving zone; a labeling zone comprising an unlabeled receptor and a labeled receptor, the unlabeled receptor located downstream of the labeled receptor and separated by a distance; and two serially oriented capture zones capable of providing quantitation of the amount of the analyte in the sample.

The present disclosure relates to devices and methods for identifying conditions in a human or animal body, such as pregnancy or ovulation. For example, the present disclosure relates to devices and methods for identifying pregnancy or ovulation, which devices and methods are adapted to mitigate the “hook effect”, thereby improving accuracy of the devices and methods.

The invention relates to a method comprising a) providing a blood sample from a subject b) determining the level of CPS-.sub.1 expression in said sample c) comparing the level of CPS-.sub.1 expression of (b) to the level of CPS-.sub.1 expression determined from a blood sample from a subject with mild to moderate fibrosis of the liver d) determining the level of glutamate in said sample e) comparing the level of glutamate of (d) to level of glutamate determined from a blood sample from a subject with mild to moderate fibrosis of the liver f) wherein if the level of glutamate of (d) and CPS-.sub.1 expression of (b) is higher than the level of glutamate and CPS-.sub.1 expression from a blood sample from a subject with mild to moderate fibrosis of the liver, it is inferred the subject has increased likelihood of having advanced or severe (F3/F4) fibrosis of the liver.

The present invention provides ST6GAL1, GALNT7, FUT8 and GCNT1 as novel biological fluid (e.g. blood or urine) biomarkers for prostate cancer. Methods for diagnosing prostate cancer or the risk of developing prostate cancer, or for monitoring prostate cancer progression (including prostate cancer relapse) and methods for treatment of prostate cancer are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens for prostate cancer or determining a subject's compliance or adherence with a prescribed treatment regimen for prostate cancer. Corresponding kits, assay devices and uses are also provided.

Disclosed herein is a novel class of isolated binding molecules including monoclonal antibodies that targets a broadly conserved epitope within the marburgvirus species. Certain aspects provide an effective treatment option for hemorrhagic fever caused by marburgviruses.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

One non-limiting and exemplary embodiment provides a metal microscopic structure capable of detecting a low-concentration analyte with high sensitivity. The metal microscopic structure includes a base member including multiple protrusions arrayed at predetermined intervals, and multiple projections made of a metal film covering the base member and configured to generate surface plasmons upon irradiation with light. A film thickness of the metal film positioned in a bottom portion of a gap between every adjacent two of the multiple projections is greater than a height of the multiple protrusions and is more than or equal to 90% and less than or equal to 100% of a film thickness of the metal film deposited on top portions of the multiple protrusions.

Disclosed are novel lanthanide(III) chelates including a pyridine 4-ethynylpyrazine subunit. These chelates have an excitation wavelength which allows excitation with UV LED.